ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

Post-LOE

Novartis

ANDAORALTABLET

Approved

Dec 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE by Novartis is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. First approved in 1996.

Drug data last refreshed 3d ago

Mechanism of Action

CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.